Shock In The Pharmaceutical Industry! The Market Capitalization of 5 Billion-Dollar Giants Has Shrunk by Over ￥100 Billion, And Wuxi AppTec Has Plunged by Nearly ￥100 Billion!

According to statistics, as of December 29, 2023, the number of listed companies in China's pharmaceutical industry reached 308, with 9 new companies listed in 2023. The total market value of pharmaceutical industry listed companies in 2023 was 462,929.3 billion yuan, down 988.98 billion yuan from 2022. There were 5 companies with market capitalization exceeding 100 billion yuan, namely, Hengrui Pharmaceuticals, Wuxi AppTec, BeiGene, ZhiFei Biological and Pianzi Hui. So, what is the current market capitalization of these 5 companies?

As of the closing on August 15, 2024, the total market capitalization of Hengrui Pharmaceuticals was 27.94 billion yuan, down 91.22 billion yuan from the end of 2023. The company is a specialized enterprise focusing on drug research, production, and sales, with its business mainly concentrated in the pharmaceutical manufacturing industry, especially in the research and sales of innovative drugs. Through cooperation with numerous enterprises and research institutions around the world, Hengrui Pharmaceuticals has achieved the overseas authorization of a number of innovative drugs, including Carvyli珠单抗， Pyrrolopyrimidine, and HRS-1167, showcasing its competitiveness and innovation capabilities in the international market.

The current total market capitalization of Wuxi AppTec is 11.64 billion yuan, down nearly 100 billion yuan from the end of 2023. The company is a comprehensive pharmaceutical R&D service provider, dedicated to advancing the drug R&D process and production services, providing breakthrough treatment solutions for patients. In the first half of this year, Wuxi AppTec achieved a revenue of 1.724 billion yuan, down 8.64% from the same period last year. Net profit attributable to the listed shareholders of BeiGene was 4.24 billion yuan, down 20.20% year-on-year.

The total market value of BeiGene was 20.06 billion yuan, up 123.69 billion yuan from the end of 2023. BeiGene is a global innovative pharmaceutical company specializing in the research and development of cancer drugs, although it has lost money for seven consecutive years, but the loss in the first half of this year has decreased. This is mainly due to the growth of product revenue, especially the sales of independently developed products BeiGene (brand name: Zebubaitini capsules) and BeiZhan (Taili Lizhuzhu injection) and the strong sales growth of Anjin authorized products. In particular, the global sales of BeiGene in the first half of the year were 80.18 billion yuan, up 122% year-on-year.

The market value of ZhiFei Biological was 5.87 billion yuan, down more than 900 billion yuan from the end of 2023. The company is an international, full-chain biotechnology enterprise integrating vaccine, biological product research, production, sales, distribution and import and export. As the domestic agent of Merck's HPV vaccine, ZhiFei Biological's revenue in the first half of the year was 4.727 billion US dollars, up 7% from last year. Merck said that 60%-70% of its HPV vaccine sales come from China, but its sales growth in the first half of the year was lower than in the past, mainly because the sales in the Chinese market decreased. As a result, Zhifei Biological achieved revenue of 11.396 billion yuan in the first quarter of this year, up by only 2%, and net profit of 1.458 billion yuan, down by 28.26%.

The current market value of Pianzihuang is 12.515 billion yuan, down by about 200 billion yuan from the end of 2023. The company's main businesses include pharmaceutical manufacturing, pharmaceutical distribution, and cosmetics, with "Pianzihuang" as its main product, covering liver disease drugs, cold and flu drugs, and dermatological drugs in multiple fields. The interim report for the first half of 2024 shows that the company's revenue for the period was about 5.65 billion yuan, up by 11.99%; net profit attributable to shareholders of the parent company was about 1.72 billion yuan, up by 11.61%. Accordingly, the company's net profit attributable to shareholders of the parent company in the second quarter was about 745 million yuan, down from the same period last year.